# Itacitinib + Everolimus in Hodgkin Lymphoma

> **NCT03697408** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Pennsylvania** · enrollment: 23 (actual)

## Conditions studied

- Classical Hodgkin Lymphoma

## Interventions

- **DRUG:** Itacitinib
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT03697408
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-02-11
- **Primary completion:** 2024-05-20
- **Final completion:** 2027-06
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03697408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03697408, "Itacitinib + Everolimus in Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03697408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*